Stoke Therapeutics (STOK) Total Non-Current Liabilities (2018 - 2026)
Stoke Therapeutics' quarterly Total Non-Current Liabilities came in at $7.6 million in Q1 2026, down 37.39% year-on-year from $12.1 million in Q1 2025, and down 6.27% quarter-over-quarter from $8.1 million in Q4 2025.
Stoke Therapeutics has reported Total Non-Current Liabilities for 9 years, with the latest figure at $7.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 37.39% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (down 37.39% YoY), and the FY2025 full-year result was $8.1 million, up 226.96% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $7.6 million, down from $8.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $53.1 million in Q1 2022, with the low at $2.5 million in Q4 2024.
- Average Total Non-Current Liabilities over 5 years is $27.1 million, with a median of $29.2 million recorded in 2024.
- Year-over-year, Total Non-Current Liabilities jumped 15832.73% in 2022 and tumbled 93.47% in 2024.
- Tracing STOK's Total Non-Current Liabilities over 5 years: stood at $39.8 million in 2022, then slipped by 4.69% to $38.0 million in 2023, then plunged by 93.47% to $2.5 million in 2024, then soared by 226.96% to $8.1 million in 2025, then decreased by 6.27% to $7.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $7.6 million (Q1 2026), $8.1 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 7.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.59 Mn |
| Dec 31, 2025 | 8.10 Mn |
| Sep 30, 2025 | 10.43 Mn |
| Jun 30, 2025 | 10.89 Mn |
| Mar 31, 2025 | 12.13 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 11.34 Mn |
| Jun 30, 2024 | 20.55 Mn |
| Mar 31, 2024 | 29.25 Mn |
| Dec 31, 2023 | 37.96 Mn |
| Sep 30, 2023 | 41.69 Mn |
| Jun 30, 2023 | 44.89 Mn |
| Mar 31, 2023 | 36.45 Mn |
| Dec 31, 2022 | 39.82 Mn |
| Sep 30, 2022 | 44.69 Mn |
| Jun 30, 2022 | 49.46 Mn |
| Mar 31, 2022 | 53.06 Mn |
| Dec 31, 2021 | 3.95 Mn |
| Sep 30, 2021 | 4.37 Mn |
| Jun 30, 2021 | 1.18 Mn |
| Mar 31, 2021 | 333,000.00 |
| Dec 31, 2020 | 422,000.00 |
| Sep 30, 2020 | 665,000.00 |
| Jun 30, 2020 | 1.01 Mn |
| Mar 31, 2020 | 1.04 Mn |
| Dec 31, 2019 | 221,000.00 |
| Sep 30, 2019 | 228,000.00 |
| Jun 30, 2019 | 18,000.00 |
| Dec 31, 2018 | 4,000.00 |